News

AddToAny

Google+ Facebook Twitter Twitter

Screening to improve mAb-based drugs

By screening potential monoclonal antibody (mAb)-based drugs solely on a measure of their colloidal stability, scientists may be able to weed out mAbs that do not respond efficiently in solution early in the drug discovery process, according to a new study.

This finding could enable researchers to overcome a major hurdle to drug development by identifying promising mAb-based therapies, which must be administered via injection, but often lack the properties necessary to succeed as solutions.

“Therapeutic antibodies that neutralise pathogens are a promising way to treat infectious disease,” said Jonathan Kingsbury, study author. “Selection of well-behaved antibodies with molecular properties that enable streamlined manufacturing, scale-up, and subcutaneous delivery is key for rapid development, particularly during a pandemic response.”

The paper says mAb solution behaviour can be predicted with 90% accuracy based on its diffusion interaction parameter.  

bit.ly/2BOGUKj


Picture Credit | Science Photo Library

Related Articles

The vaccine race

With more than 150 COVID-19 vaccines in development, we put the three front-runners under the microscope and look at the incredible, unprecedented development work of the last year.

Smallpox, salmonella and sacrifice

Stephen Mortlock looks back at the history of the Aztec civilisation, the diseases that struck and the treatments that were created.

Urgent need for early COVID-19 treatments

COVID-19 treatments for people with early infection are needed urgently, according to Anthony S Fauci, Director of the US National Institute of Allergy and Infectious Diseases.

What is long COVID?

Dr David Strain, a Senior Clinical Lecturer, is heading up the British Medical Association’s work on the long-term impact of COVID-19. Here he explains what we know so far about long COVID.

Top